Overview


With the increasing expansion of the biopharmaceutical industry, many manufacturers are facing multiple problems like dearth of expertise and systematic equipment during in-house manufacturing. The availability of external funding and biotech manufacturing has led to a spurt of bio companies in early stage as they are the primary CMO customers due to their lack of capability of developing vigorous manufacturing operations. Multiple established CMOs like Lonza and Boehringer Ingelheim have received competition from many emerging CMOs in this high-volume market. For example, Samsung entered this market as Samsung Biologics in 2013 and has since expanded their bioreactor capacities to witness growth in this sector. The company currently owns three plants with over 360,000 litres of capacity and the fourth plant is under assessment, which shall be located outside South Korea. Additionally, technological breakthroughs in bioprocessing have been crucial in the development of CMOs by working on issues like need of a batch-wise changeover and high production costs. Bioprocessing systems that can use once have proven to be significant in reducing the total scale-up and production costs. With strategic acquisitions and mergers, the biopharmaceutical contract manufacturing market growth is expected to grow substantially over the forecasted timeframe. However, established companies consider outsourcing as unfeasible owing to limited management oversight and loss of strategic control, resulting in these companies choosing in-house manufacturing operations.

  • Boehringer Ingelheim GmbH
  • Lonza
  • Inno Biologics Sdn Bhd
  • Rentschler Biotechnologie GmbH
  • JRS Pharma
  • AGC Biologics
  • ProBioGen
  • Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  • Toyobo Co., Ltd.
  • Samsung BioLogics
  • Thermo Fisher Scientific, Inc.
  • Binex Co., Ltd.
  • WuXi Biologics
  • AbbVie, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Source

  • Mammalian Source 
  • Non-Mammalian Source

By Product

  • Biosimilars
  • Biologics
    • Monoclonal antibodies (MABs)
    • Recombinant Proteins
    • Vaccines
    •  Antisense, RNAi, & Molecular Therapy
    • Others

By Services 

  • Product Development
    • Downstream
    • Upstream
  • Fill and Finish Operations
  • Analytical and QC Testing
  • Packaging

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

The market is categorised into source, product, services and region. The source segment is diversified into mammalian source and mon-mammalian source. The mammalian contract manufacturing segment is anticipated to hold the largest biopharmaceutical contract manufacturing market share, and this can be credited to increased acceptance rate of mammalian system for producing biologics. Furthermore, most of the biopharma products currently in the pipeline are expressed by mammalian source. Companies like Charles River and Lonza have heavily invested in expanding their manufacturing facilities of mammalian cell culture for biosimilars and biologics. The product segment is classified into biosimilars and biologics. The biologics segment dominated the market in 2018 and this primarily owing to the massive commercial acceptance of biologics by the market. The service segment is fragmented into process development, fill and finish operations, analytical and QC testing and packaging.

The North America region subjugated the market in 2017 owing to a strong presence of biopharma facilities in the Unites States along with increased research and development activities in biopharma sector. The Asia Pacific region, however, shall grow at a significant rate during the forecast period and this is due to low operating and manufacturing costs provided by countries like India.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the global Biopharmaceutical Contract Manufacturing Market By Source, By Product, By Services and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market 
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization services offered are free of charge with purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Biopharmaceutical Contract Manufacturing Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework on Country Level
         6.1 . Reimbursement Framework
         6.2 . Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Biopharmaceutical Bioseparation Systems Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.   Market Analysis tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.   Biopharmaceutical Contract Manufacturing Market, By Source Historical Analysis and Forecast 2023-2031 (USD million)
    •   1. Mammalian Source
        2. Non-Mammalian Source

  • 8.   Biopharmaceutical Contract Manufacturing Market, By Product Historical Analysis and Forecast 2023-2031 (USD million)
    •   1. Biosimilars
        2. Biologics
         2.1 . Monoclonal antibodies (MABs)
         2.2 . Recombinant Proteins
         2.3 . Vaccines
         2.4 . Antisense, RNAi, and Molecular Therapy
         2.5 . Others

  • 9.   Biopharmaceutical Contract Manufacturing Market, By Services Historical Analysis and Forecast 2023-2031 (USD million)
    •   1. Product Development
         1.1 . Downstream
         1.2 . Upstream
        2. Fill and Finish Operations
        3. Analytical and QC Testing
        4. Packaging

  • 10.   North America Biopharmaceutical Contract Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Mn) Analysis By Country, 2017-2022
         2.1. U.S.
         2.2. Canada
         2.3. Mexico
         2.4. Rest of North America
        10.3 . Market Size (USD Mn) Forecast for North America 2023-2031

  • 11.   Latin America Biopharmaceutical Contract Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Regional Market Trends
        3. Historical Market Size (US$ Mn) Analysis By Country, 2017-2022
         3.1. Brazil
         3.2. Venezuela
         3.3. Argentina
         3.4. Rest of Latin America
        11.4 . Market Size (US$ Mn) Forecast for Latin America 2023-2031

  • 12.   Europe Biopharmaceutical Contract Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (US$ Mn) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5 . Switzerland
         2.6. Spain
         2.7. Russia
         2.8. Poland
         2.9. Rest of Western Europe
        3. Market Size (US$ Mn) Forecast for North America 2023-2031

  • 13.   Asia Pacific Biopharmaceutical Contract Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Mn) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. Singapore
         2.4. Korea
         2.5. India
         2.6. Australia and New Zealand
         2.7. ASEAN
         2.8. Rest of Asia Pacific
        3. Market Size (US$ Mn) Forecast for North America 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Mn) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (US$ Mn) Forecast for MEA 2023-2031

  • 15.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 16.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
    •   1. Boehringer Ingelheim GmbH
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Lonza
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Inno Biologics Sdn Bhd
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Rentschler Biotechnologie GmbH
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. JRS PHARMA
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. AGC Biologics
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. ProBioGen
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Fujifilm Diosynth Biotechnologies U.S.A. Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Toyobo Co., Ltd.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
         10. Samsung BioLogics
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Thermo Fisher Scientific Inc.
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Binex Co. Ltd.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. WuXi Biologics
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. AbbVie Inc.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview

  • 17.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                   administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.  Competitive Intelligence and Competitive Matrix
    •   1. Competitive Intelligence
        2. Competitive Matrix

  • 19.   Major Deals and Strategic Alliances Analysis
    •   1. Joint ventures
        2. Mergers and acquisitions
        3. Licensing and partnerships
        4. Technology Collaborations
        5. Strategic Divestments
        6. Market Entry Strategies

  • 20.  Relevant Case Studies and Latest News Updates
    •   

  • 21.  Key Market Takeaway Points from the Market Analysts at Future Market Analytics
    •   

Partner

Our Clients